In December 2013, OncoMed and Celgene Corporation announced a broad strategic collaboration on research and development programs
directed to the discovery and development of novel biologic therapeutics. In exchange for significant financial commitments, Celgene
has gained exclusive options to OncoMed's rosmantuzumab (anti-RSPO3, OMP-131R10) and anti-TIGIT (OMP-313M32) programs. OncoMed retains
co-development and co-commercialization rights for the rosmantuzumab program in the U.S. OncoMed received a $177.25 million upfront
payment, including a $22.25 million equity investment. The collaboration also includes option exercise payments and payments for achievement
of development, regulatory and commercial milestones, paid on a per-program basis. OncoMed will also receive royalty payments based on
future product sales.
In June 2010, OncoMed entered into a strategic alliance with Bayer HealthCare to discover, develop and commercialize novel anti-cancer stem cell therapeutics. Under the agreement, Bayer and OncoMed agreed to collaborate on the development of up to five agents targeting the Wnt signaling pathway. Two products, vantictumab (anti-Fzd, OMP-18R5) and ipafricept (Fzd8-Fc, OMP-54F28) emerged from these discovery efforts and advanced into clinical studies. Upfront and milestone payments of over $90 million were received from Bayer to support the discovery and development of these therapeutics through multiple Phase 1b clinical trials. In April 2017, Bayer notified OncoMed that they would not be seeking to exercise their option to in-license vantictumab and ipafricept. OncoMed retains worldwide development and commercialization rights to vantictumab, ipafricept and all other Wnt pathway biologics under the collaboration. The small molecule program under the companies' collaboration continues without change. For any small molecule candidates (for which Bayer will lead discovery and development efforts), OncoMed's payments could total up to $112 million per program in addition to single digit percentage royalties on net product sales.